Skip to main content

Table 6 Demographics of study participants in the mITT population—individual and pooled studies 030, 043 and 045

From: Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries

 

Placebo

Tafenoquine 200-mg weekly

Total

030

043

045

Pooled

030

043

045

Pooled

030

043

045

Pooled

N

93

60

94

247

99

55

91

245

192

115

185

492

Age (years)

 Median

30

32

48

38

25

34

48

35

27

34

48

36

 Min, max

17, 56

18, 55

17, 60

17, 60

17, 54

18, 54

18, 69

17, 69

17, 56

18, 55

17, 69

17, 69

Age categories (years)

 <20

18 (19.4 %)

13 (21.7 %)

5 (5.3 %)

36 (14.6 %)

19 (19.2 %)

9 (16.4 %)

4 (4.4 %)

32 (13.1 %)

37 (19.3 %)

22 (19.1 %)

9 (4.9 %)

68 (13.8 %)

 20–29

25 (26.9 %)

16 (26.7 %)

14 (14.9 %)

55 (22.3 %)

40 (40.4 %)

15 (27.3 %)

6 (6.6 %)

61 (24.9 %)

65 (33.9 %)

31 (27.0 %)

20 (10.8 %)

116 (23.6 %)

 30–39

23 (24.7 %)

9 (15.0 %)

9 (9.6 %)

41 (16.6 %)

17 (17.2 %)

12 (21.8 %)

20 (22.0 %)

49 (20.0 %)

40 (20.8 %)

21 (18.3 %)

29 (15.7 %)

90 (18.3 %)

 40–49

16 (17.2 %)

19 (31.7 %)

27 (28.7 %)

62 (25.1 %)

12 (12.1 %)

11 (20.0 %)

19 (20.9 %)

42 (17.1 %)

28 (14.6 %)

30 (26.1 %)

46 (24.9 %)

104 (21.1 %)

 ≥50

11 (11.8 %)

3 (5.0 %)

39 (41.5 %)

53 (21.5 %)

11 (11.1 %)

8 (14.5 %)

42 (46.2 %)

61 (24.9 %)

22 (11.5 %)

11 (9.6 %)

81 (43.8 %)

114 (23.2 %)

Sex

 Male

59 (63.4 %)

34 (56.7 %)

62 (66.0 %)

155 (62.8 %)

65 (65.7 %)

38 (69.1 %)

59 (64.8 %)

162 (66.1 %)

124 (64.6 %)

72 (62.6 %)

121 (65.4 %)

317 (64.4 %)

 Female

34 (36.6 %)

26 (43.3 %)

32 (34.0 %)

92 (37.2 %)

34 (34.3 %)

17 (30.9 %)

32 (35.2 %)

83 (33.9 %)

68 (35.4 %)

43 (37.4 %)

64 (34.6 %)

175 (35.6 %)

Height (cm)

 Median

NC

169.5

166.5

167

NC

170

166

168

NC

170

166

168

 Min, max

 

146, 192

150, 189

146, 192

 

148, 194

149, 188

148, 194

 

146, 194

149, 189

146, 194

Weight (kg)

 Median

60

60

53

57

60.5

61

50

57

60

60

52

57

 Min, max

44, 81

39, 83

35, 73

35, 83

42, 90

45, 79

35, 68

35, 90

42, 90

39, 83

35, 73

35, 90

  1. Percentages are based on the number of study participants in each treatment group from the mITT population (N)
  2. Max maximum, Min minimum, mITT modified intent-to-treat, N number of subjects, SD standard deviation